Acetylsalicylic acid (ASS), which is usually administered to patients at increased cardiovascular risk, counteracts the inflammation-induced suppression of Ntn1 secretion by the endothelium and significantly reduces plaque sizes in a murine ApoE−/− model of atherosclerosis [61]. Here, NTN1 is linked to atherosclerosis.